Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences | SpringerLink
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Molecules | Free Full-Text | Development of CDK4/6 Inhibitors: A Five Years Update
Medicinrådets protokol for vurdering vedr. alpelisib til ER+HER2- brystkræft med PIK3CA-mutation-vers. 1.0
CDK4/6 inhibitors: a novel strategy for tumor radiosensitization | Journal of Experimental & Clinical Cancer Research | Full Text
CDK4/6 inhibition in breast cancer: current practice and future directions. - Abstract - Europe PMC
Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies | Acta Pharmacologica Sinica
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib - ScienceDirect
Cancers | Free Full-Text | Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study
Medicinrådets vurdering vedr. alpelisib i komb. med fulvestrant til metastatisk brystkræft-vers 1.0
A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib - ScienceDirect
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies: Trends in Cancer
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review. - Abstract - Europe PMC
The application and prospect of CDK4/6 inhibitors in malignant solid tumors | Journal of Hematology & Oncology | Full Text
Potential combination strategies for CDK4/6 inhibitors. CDK4/6... | Download Scientific Diagram
Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation - ScienceDirect
The application and prospect of CDK4/6 inhibitors in malignant solid tumors | Journal of Hematology & Oncology | Full Text
Medicinrådets lægemiddelrek. og beh.vejl. vedr. CDK46-hæmmere til ER+HER2- lokalt fremskreden eller metastatisk brystkræft
Frontiers | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status | SpringerLink
CDK 4/6-hæmmer plus førstelinjebehandling forlænger overlevelsen ved metastaserende brystkræft - Dagens Medicin
ASCO 2016 - Brystkræft
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer - ScienceDirect
Frontiers | CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. - Abstract - Europe PMC
